Ramdevbaba Solvent Limited — Results, 30-06-2025: Reply to Clarification- Financial results

Ramdevbaba Solvent Limited has announced a board meeting to consider and approve the financial results for the quarter and half-year ended 31 March 2025. The company reported its audited standalone and consolidated financial results with an unmodified auditor’s opinion by Borkar & Muzumdar, Chartered Accountants.

**Standalone Financial Highlights (Year ended 31 March 2025):**

- Revenue from Operations: ₹926.43 Cr (₹686.44 Cr in FY24)

- Total Income: ₹935.59 Cr (₹692.99 Cr)

- Total Expenses: ₹915.45 Cr (₹675.27 Cr)

- Profit Before Tax (PBT): ₹20.14 Cr (₹17.72 Cr)

- Profit After Tax (PAT): ₹15.03 Cr (₹13.03 Cr)

- Earnings Per Share (Basic & Diluted): ₹6.88 (₹8.60)

- Equity Share Capital: ₹22.86 Cr

- Other Equity: ₹128.66 Cr

**Consolidated Financial Highlights (Year ended 31 March 2025):**

- Revenue from Operations: ₹926.69 Cr (₹686.44 Cr in FY24)

- Total Income: ₹935.85 Cr (₹692.99 Cr)

- Total Expenses: ₹915.77 Cr (₹675.27 Cr)

- Profit Before Tax (PBT): ₹20.08 Cr (₹17.72 Cr)

- Profit After Tax (PAT) attributable to shareholders: ₹15.00 Cr (₹13.03 Cr)

- Earnings Per Share (Basic & Diluted): ₹6.86 (₹8.60)

- Equity Share Capital: ₹22.86 Cr

- Other Equity: ₹128.63 Cr

**Balance Sheet (Standalone vs Consolidated as of 31 March 2025):**

- Total Assets Standalone: ₹288.85 Cr; Consolidated: ₹481.99 Cr

- Shareholders’ Funds Standalone: ₹151.52 Cr; Consolidated: ₹151.49 Cr

- Non-Current Borrowings Standalone: ₹26.20 Cr; Consolidated: ₹197.35 Cr

- Current Borrowings Standalone: ₹68.01 Cr; Consolidated: ₹69.39 Cr

- Inventories Standalone: ₹75.21 Cr; Consolidated: ₹77.61 Cr

- Trade Receivables Standalone & Consolidated: ₹32.30 Cr

**Cash Flow Summary (Standalone vs Consolidated FY25):**

- Operating Cash Flow: Standalone ₹-12.03 Cr; Consolidated ₹-0.74 Cr

- Investing Cash Flow: Standalone ₹-23.96 Cr; Consolidated ₹-127.56 Cr (reflecting higher Capex and intangible asset investment in consolidated)

- Financing Cash Flow: Standalone ₹39.05 Cr; Consolidated ₹125.14 Cr

- Net Increase/(Decrease) in Cash & Cash Equivalents: Standalone ₹3.06 Cr; Consolidated ₹-3.16 Cr

**Fundraising and Utilisation:**

- IPO proceeds of ₹44.62 Cr have been mostly utilized for manufacturing setup, repayment of borrowings, working capital, and general corporate purposes with no deviations reported.

- Preferential Issue proceeds of ₹26.04 Cr have been partially utilized; ₹7.91 Cr remains unutilized pending receipt from warrant holders.

- The company has received listing approvals and completed allotments as planned.

**Key Appointments:**

- M/s Deepa Agrawal & Co., Cost Accountants as Cost Auditor for FY 2025-26

- M/s T.S. Tendulkar & Co., Practicing Company Secretaries as Secretarial Auditor for five years (subject to shareholder approval)

- M/s Girish N. Mundada & Co., Chartered Accountants as Internal Auditor for FY 2025-26

**Operational Notes:**

- The company operates in a single segment.

- Two subsidiaries: RBS Renewables Pvt Ltd (50.82% stake) and Too Gud FMCG Products Pvt Ltd (65% stake, no business activity yet).

- Capital structure increased via IPO and preferential issues; share capital stands at ₹22.86 Cr.

- Depreciation follows management-estimated useful life certified by a chartered engineer, differing from the Companies Act schedule.

- Certain income tax litigations pending; accidental fire loss yet to be quantified.

**Related Party Transactions (RPT) Policy:**

- The company has a comprehensive RPT policy aligned with Companies Act and SEBI Listing Regulations.

- RPT approvals and disclosures conform to prescribed thresholds and procedures, encompassing Audit Committee and Board oversight and shareholder approvals when required.

Overall, Ramdevbaba Solvent Limited shows revenue growth and improvement in profit after tax compared to the previous year, with a healthy equity base and significant investments in property, plant, and equipment. Fundraising proceeds are substantially utilized for stated objectives without deviations. The company maintains robust governance frameworks, including auditor appointments and related party transaction policies, supporting transparency and compliance.